Schedule 13G ownership disclosure
Allogene Therapeutics Inc
Common Stock, par value $0.001 per share · CUSIP: 019770106
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Lynx1 Capital Management LP
Shares: 10,874,723.00 · Class: 5.2%
- Weston Nichols
Shares: 10,874,723.00 · Class: 5.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-000983
- Form type
- SCHEDULE 13G
- Filer
- Allogene Therapeutics, Inc.
- CIK
- CIK 1737287
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership